Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.71 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.71 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.71 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | ADK | P55263 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KLK1 | P06870 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31661863 | 1.00 | CSNK1A1 (0.71) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL9234252 | 0.83 | CSNK1A1 (0.71) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL6825869 | 0.83 | CSNK1A1 (1.00) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| Water SCHEMBL30473073 | 0.82 | CSNK1A1 (0.97) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL10714674 | 0.79 | CSNK1A1 (0.76) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL30965100 | 0.78 | CSNK1A1 (0.73) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL297622 | 0.78 | CSNK1A1 (0.73) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL9287236 | 0.78 | NISCH (0.64) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL15478263 | 0.77 | CSNK1A1 (0.71) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL11566235 | 0.77 | CSNK1A1 (0.71) | CSNK1A1TYRO3DYRK1BNISCHMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0279787-A1 | Pharmaceutical compositions with synergistic antisecretory action for the healing of gastroduodenal ulcer | ISTITUTO DE ANGELI S.p.A. (IT) | 1988-08-24 | — | — | EP | claimed |
| US-20230349922-A1 | H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer | UNIVERSITÉ DE STRASBOURG (FR) | 2023-11-02 | — | — | US | disclosed |
| EP-4196793-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | Université de Strasbourg (FR) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022034121-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | UNIVERSITÉ DE STRASBOURG (FR) | 2022-02-17 | — | — | WO | disclosed |
| US-8277782-B2 | Antiinflammatory agent, metalloproteinase inhibitor, anti-oxidant and modifier of cell redox status, vitamins, inhibitor of activation of nuclear factor kappa beta | THE PROCTER & GAMBLE COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| EP-1294367-B1 | ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT | PROCTER & GAMBLE (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20060193790-A1 | Promoting whole body health | THE PROCTER & GAMBLE COMPANY | 2006-08-31 | — | — | US | disclosed |
| EP-1294367-A2 | ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT | The Procter & Gamble Company (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002002096-A2 | ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
| US-5364616-A | Use of H-2 antagonists for treatment of gingivitis | THE PROCTER & GAMBLE COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| US-5294433-A | Dentistry | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-15 | — | — | US | disclosed |
| WO-1993020815-A1 | USE OF H-2 ANTAGONISTS FOR TREATMENT OF GINGIVITIS | THE PROCTER & GAMBLE COMPANY (US) | 1993-10-28 | — | — | WO | disclosed |
| EP-0279787-A1 | Pharmaceutical compositions with synergistic antisecretory action for the healing of gastroduodenal ulcer | ISTITUTO DE ANGELI S.p.A. (IT) | 1988-08-24 | — | — | EP | disclosed |
| EP-0279787-A1 | Pharmaceutical compositions with synergistic antisecretory action for the healing of gastroduodenal ulcer | ISTITUTO DE ANGELI S.p.A. (IT) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060193790-A1 | Promoting whole body health | IFNG, TNF, TLR6 | CSNK1A1 4152/4885TYRO3 1382/4885DYRK1B 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.